Recently, adjuvant atezolizumab (anti‐programmed cell death‐ligand 1 [anti‐PD‐L1] blockade) improved disease‐free survival (DFS) compared with best supportive care after platinum‐combination chemotherapy for PD‐L1 positive resected stage II–IIIA NSCLC.17 The gene discussed is CD274; the disease is non-small cell lung carcinoma.